コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ted to the intensive care unit due to severe community acquired pneumonia.
2 PIV serotypes in patients hospitalized with community acquired pneumonia.
3 s known to increase the risk and severity of community acquired pneumonia.
4 recognized as important etiologic agents in community acquired pneumonia.
5 een PIV and other pathogens in patients with community-acquired pneumonia.
6 is the cornerstone of medical management for community-acquired pneumonia.
7 iae is the most common causative pathogen in community-acquired pneumonia.
8 ute respiratory distress syndrome induced by community-acquired pneumonia.
9 treatment of Asian patients with PORT III-IV community-acquired pneumonia.
10 ute respiratory distress syndrome induced by community-acquired pneumonia.
11 of Asian patients admitted to hospital with community-acquired pneumonia.
12 ide therapy for critically ill patients with community-acquired pneumonia.
13 her regimens in critically ill patients with community-acquired pneumonia.
14 factor (MIF) have been linked to the risk of community-acquired pneumonia.
15 e of hospitalization of patients affected by community-acquired pneumonia.
16 r amoxicillin for children hospitalized with community-acquired pneumonia.
17 al use of corticosteroids in severe cases of community-acquired pneumonia.
18 secutively collected patients diagnosed with community-acquired pneumonia.
19 uman nasopharynx and is the leading cause of community-acquired pneumonia.
20 ealthcare-associated pneumonia (HCAP) versus community-acquired pneumonia.
21 ptococcus pneumoniae is the leading cause of community-acquired pneumonia.
22 . the other for elderly patients with severe community-acquired pneumonia.
23 as patients admitted due to sepsis or severe community-acquired pneumonia.
24 ung injury in African American children with community-acquired pneumonia.
25 iae is the most common causative organism in community-acquired pneumonia.
26 entilation in African American children with community-acquired pneumonia.
27 nd skin structure infection and hospitalized community-acquired pneumonia.
28 -negative bacterium that causes 10 to 20% of community-acquired pneumonia.
29 ommonly isolated organism from patients with community-acquired pneumonia.
30 ated with increased inflammation and risk of community-acquired pneumonia.
31 F expression may have a beneficial effect in community-acquired pneumonia.
32 Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia.
33 linical trial involving patients with severe community-acquired pneumonia.
34 merging as an important etiological agent of community-acquired pneumonia.
35 isolates resistant to first-line therapy for community-acquired pneumonia.
36 nfections causing sinusitis, bronchitis, and community-acquired pneumonia.
37 rity criteria in a clinical trial for severe community-acquired pneumonia.
38 care unit (ICU) patients with sepsis due to community-acquired pneumonia.
39 respiratory failure and ARDS in adults with community-acquired pneumonia.
40 ed for mechanical ventilation in adults with community-acquired pneumonia.
41 accharide vaccine alters the overall risk of community-acquired pneumonia.
42 pneumococcal pneumonia among 149 adults with community-acquired pneumonia.
43 human pathogen and the most common cause of community-acquired pneumonia.
44 rm of acute to subacute antibiotic-resistant community-acquired pneumonia.
45 ed by fat embolism and infection, especially community-acquired pneumonia.
46 onfirm the efficacy of TMP-SMZ in preventing community-acquired pneumonia.
47 l pneumonia among hospitalized patients with community-acquired pneumonia.
48 lidated--for treating adult outpatients with community-acquired pneumonia.
49 treatment strategies for adult patients with community-acquired pneumonia.
50 ors for poor outcomes in adult patients with community-acquired pneumonia.
51 Mycoplasma pneumoniae is a major cause of community-acquired pneumonia.
52 m monotherapy for children hospitalized with community-acquired pneumonia.
53 to compare these with the same parameters in community-acquired pneumonia.
54 gnosed diabetes mellitus was prevalent among community-acquired pneumonia.
55 ged 1-59 months enrolled in a large study of community-acquired pneumonia.
56 rveillance study of adults hospitalized with community-acquired pneumonia.
57 making analysis of Sepsis-3 in patients with community-acquired pneumonia.
58 ing acute respiratory disease (ARD), such as community-acquired pneumonia.
59 emic inflammatory response syndrome, 100 for community-acquired pneumonia, 112 for urinary tract infe
60 nrolled 402 adults > or = 18 yrs of age with community-acquired pneumonia; 158 were white, 243 were A
63 , 1428 cohort members were hospitalized with community-acquired pneumonia, 3061 were assigned a diagn
64 d ratio, 1.21; 95% CI, 1.06-1.36) and severe community-acquired pneumonia (adjusted hazard ratio, 1.5
66 Incidence estimates of hospitalizations for community-acquired pneumonia among children in the Unite
68 ureus is a significant cause of hospital and community acquired pneumonia and causes secondary infect
70 nary sarcoidosis, pulmonary tuberculosis, to community acquired pneumonia and primary lung cancer and
71 ospitals involving patients with both severe community-acquired pneumonia and a high inflammatory res
72 eumoniae is the primary etiological agent of community-acquired pneumonia and a major cause of mening
73 gionella are recognised as a common cause of community-acquired pneumonia and a rare cause of hospita
74 ac complications are common in patients with community-acquired pneumonia and are associated with inc
76 to those provided by etiological studies of community-acquired pneumonia and emphasize the potential
77 o UK intensive care units with sepsis due to community-acquired pneumonia and evidence of organ dysfu
78 reptococcus pneumoniae is a leading cause of community-acquired pneumonia and gram-positive sepsis.
79 y helpful in the evaluation of patients with community-acquired pneumonia and has also been recommend
80 sma pneumoniae accounts for 20 to 30% of all community-acquired pneumonia and has been associated wit
82 ccal infection in epidemiological studies of community-acquired pneumonia and in vaccine efficacy tri
83 ntigen detection assay were used to identify community-acquired pneumonia and invasive pneumococcal d
85 e (the pneumococcus) is the leading cause of community-acquired pneumonia and is now recognized to be
86 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and nasal carriage is a pre
87 dividually and in combination, in diagnosing community-acquired pneumonia and predicting short-term r
88 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and results in over 1 milli
89 udomonas pneumonia, and associations between community-acquired pneumonia and risks or outcomes have
90 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and sepsis, with adult hosp
91 Streptococcus pneumoniaeis a major cause of community-acquired pneumonia and septicemia in adults.
92 ty of care for black vs. white patients with community-acquired pneumonia and suggested that disparit
93 on treatment in critically ill patients with community-acquired pneumonia and support current guideli
94 pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive p
95 oniae continues to be a significant cause of community-acquired pneumonia and, on rare occasions, man
96 infections, including tracheobronchitis and community acquired pneumonia, and is linked to asthma an
97 for trauma; 15.0% vs 25.4%, p = 4.4 x 10 for community-acquired pneumonia, and 7.1% vs 20.0%, p = 3.4
98 ax, 71.8% specific (64.8-78.1) compared with community-acquired pneumonia, and 95.6% specific (90.0-9
99 reptococcus pneumoniae, the leading cause of community-acquired pneumonia, and group B Streptococcus,
100 possibly spontaneous bacterial peritonitis, community-acquired pneumonia, and infection with Mycobac
101 , nonbacteremic and noninvasive pneumococcal community-acquired pneumonia, and invasive pneumococcal
102 during a lower respiratory tract infection, community-acquired pneumonia, and pneumonia associated w
104 he guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam an
106 ving extracorporeal membrane oxygenation for community-acquired pneumonia between 2002 and 2012.
107 re also detected in isolates responsible for community-acquired pneumonia, burn infections, bacteremi
108 e infections of humans are a common cause of community acquired pneumonia but have also been linked t
109 high level of certainty in the diagnosis of community-acquired pneumonia, but the absence of vital s
111 ographics and comorbidities of patients with community acquired pneumonia (CAP) vary enormously but s
112 Coccidioidomycosis (CM) is a common cause of community acquired pneumonia (CAP) where CM is endemic.
114 Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia (CAP) across patient popula
116 , 5, 7F, and 19A were the most implicated in community-acquired pneumonia (CAP) after implementation
117 linical effectiveness of PPV23 in preventing community-acquired pneumonia (CAP) among the general pop
119 en aged <18 years who were hospitalized with community-acquired pneumonia (CAP) and children asymptom
120 neumoniae causes a substantial proportion of community-acquired pneumonia (CAP) and healthcare-associ
122 om a previously healthy 26-year-old man with community-acquired pneumonia (CAP) and multiple brain ab
123 lected urine from hospitalized patients with community-acquired pneumonia (CAP) and performed a compr
124 , rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsi
127 of pneumonia, causing about 15-20% of adult community-acquired pneumonia (CAP) and up to 40% of case
128 ent pneumonia following hospitalization with community-acquired pneumonia (CAP) are poorly understood
131 ggest that statins may benefit patients with community-acquired pneumonia (CAP) due to antiinflammato
132 iate Mycoplasma pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies
133 availability, but hospitalized patients with community-acquired pneumonia (CAP) generally are treated
135 nfectious Diseases Society of America (IDSA) Community-acquired Pneumonia (CAP) guidelines were devel
137 ng proton pump inhibitor (PPI) exposure with community-acquired pneumonia (CAP) have reported either
139 quent lack of a microbiological diagnosis in community-acquired pneumonia (CAP) impairs pathogen-dire
140 data describing the etiology and outcome of community-acquired pneumonia (CAP) in sub-Saharan Africa
148 if sex-related survival difference following community-acquired pneumonia (CAP) is due to differences
150 ficance of viruses detected in patients with community-acquired pneumonia (CAP) is often unclear.
152 ng US children (<18 years) hospitalized with community-acquired pneumonia (CAP) is poorly understood.
155 is is a prospective longitudinal study of 63 community-acquired pneumonia (CAP) patients and 21 healt
158 important features and management issues of community-acquired pneumonia (CAP) that are especially r
159 ity and a parallel inception cohort study of community-acquired pneumonia (CAP) to assess risk of sev
160 In a prospective study, the etiology of community-acquired pneumonia (CAP) was investigated amon
161 ults with low pGSN at hospital admission for community-acquired pneumonia (CAP) were at high risk for
162 tment for patients with clinically suspected community-acquired pneumonia (CAP) who are admitted to n
163 t had culture-positive tuberculosis, 100 had community-acquired pneumonia (CAP), 26 had P. jirovecii
164 k of invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP), it is unclear whethe
165 l evaluation of changes in hospital care for community-acquired pneumonia (CAP), little is known abou
166 e plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common caus
167 of pure viral sepsis in adult patients with community-acquired pneumonia (CAP), using the Sepsis-3 d
188 dy of 445 pneumonia patients, including both community-acquired pneumonia (CAP; n = 124) and HCAP (n
190 ty-acquired pneumonia included in the German Community-Acquired Pneumonia Competence Network (CAPNETZ
191 al multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010
193 hage, trauma, acute renal failure, or severe community-acquired pneumonia did not differ statisticall
194 vasive pneumococcal disease and pneumococcal community-acquired pneumonia differed by age and between
195 11 hospitals in West Midlands, England, with community-acquired pneumonia during 1996-1999 were inter
196 nary samples from 196 Tunisian patients with community-acquired pneumonia during the period 2009-2010
198 a cohort study including adult patients with community-acquired pneumonia from two Spanish university
199 2 group than in the influenza group and the community-acquired pneumonia group (1.91 vs 1.48 vs 1.53
200 erican Thoracic Society definition of severe community-acquired pneumonia had high specificity but lo
201 antibiotics within 4 hours to patients with community-acquired pneumonia has been criticized as a qu
202 IPD and the most resource-intensive type of community-acquired pneumonia, hospital-treated pneumonia
203 surveillance for radiographically confirmed community-acquired pneumonia hospitalizations among chil
204 nter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted
205 developed to predict the 30 day mortality in community acquired pneumonia; however, several guideline
207 g et al. proposed a new definition of severe community-acquired pneumonia in 1999, which was adopted
209 nts, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age o
210 CV13) against first episodes of vaccine-type community-acquired pneumonia in adults aged >/=65 years
212 Coccidioidomycosis is a common cause of community-acquired pneumonia in areas of the southwester
213 Child Health (PERCH) study, a large study of community-acquired pneumonia in children aged 1-59 month
214 ination is associated with a reduced risk of community-acquired pneumonia in immunocompetent elderly
215 pneumoniae is the leading cause of bacterial community-acquired pneumonia in persons of all ages.
217 olipid lysoPCaC26:1 identified patients with community-acquired pneumonia in sepsis or severe sepsis/
218 butes to the pathogenesis of childhood acute community-acquired pneumonia in settings with a high tub
219 e analyses of risk and prognostic factors in community-acquired pneumonia in the elderly have found t
220 y-seven patients met the criteria for severe community-acquired pneumonia in the emergency department
221 usefulness as prompt tools for patients with community-acquired pneumonia in the emergency department
222 d workers and 1% in healthcare workers); and community-acquired pneumonia in working-age adults (PAF,
223 dromes (including bloodstream infections and community-acquired pneumonia) in children and neonates (
225 ny and Austria encompassing 1961 adults with community-acquired pneumonia included in the German Comm
226 iency virus (HIV) infection hospitalized for community-acquired pneumonia, including Pneumocystis car
227 other infections such as bacterial or viral community-acquired pneumonia, influenza, and tuberculosi
228 1 are associated with unfavorable outcome in community-acquired pneumonia, intra-abdominal infections
230 e severe lung injury in children who develop community-acquired pneumonia is associated with variatio
231 l management of patients suspected of having community-acquired pneumonia is challenging because of t
237 ococcus pneumoniae, the most common cause of community-acquired pneumonia, is increasing in the Unite
238 Streptococcus pneumoniae is a major cause of community-acquired pneumonia leading to high mortality r
239 ccus pneumoniae, the most common pathogen of community-acquired pneumonia, led to exclusive damage in
240 orticoids in the management of patients with community-acquired pneumonia, liver failure, pancreatiti
241 f almost 10,000 critically ill patients with community-acquired pneumonia, macrolide use was associat
242 nes on the management of adult patients with community-acquired pneumonia.Methods: A multidisciplinar
243 sepsis due to fecal peritonitis (n = 117) or community-acquired pneumonia (n = 126), and of control s
244 ute respiratory distress syndrome induced by community-acquired pneumonia (n=10), CXCR1 and CXCR2 exp
245 odes of vaccine-type strains of pneumococcal community-acquired pneumonia, nonbacteremic and noninvas
246 21.8 to 62.5), nonbacteremic and noninvasive community-acquired pneumonia occurred in 33 persons in t
247 s of infections due to vaccine-type strains, community-acquired pneumonia occurred in 49 persons in t
248 37.7%, 41.1%, and 75.8%, respectively), and community-acquired pneumonia occurred in 747 persons in
249 on was not associated with a reduced risk of community-acquired pneumonia (odds ratio 0.92, 95% CI 0.
250 nhalational anthrax cases than in either the community-acquired pneumonia or influenza-like illness c
251 rism-related anthrax) with 376 controls with community-acquired pneumonia or influenza-like illness.
252 f recombinant TFPI to treat severe sepsis in community-acquired pneumonia or to achieve improved engr
253 88; n = 921 participants), and S. pneumoniae community-acquired pneumonia (OR = 2.15; 95% CI = 1.32-3
254 gh-risk antibiotic in the prior 90 days, had community-acquired pneumonia, or did not have a total an
256 est differences in circulating biomarkers in community-acquired pneumonia, perhaps as a result of hea
257 spitalisations for non-invasive pneumococcal community acquired pneumonia (PnCAP) to evaluate long-te
258 ospitalizations for noninvasive pneumococcal community-acquired pneumonia (PnCAP) to evaluate long-te
260 hospitalized with radiographically confirmed community-acquired pneumonia published from January 1, 1
261 omised patients and healthy individuals with community-acquired pneumonia remains an unmet medical ne
262 is a recommended treatment for patients with community-acquired pneumonia requiring hospital admissio
263 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a
264 lculated population-based incidence rates of community-acquired pneumonia requiring hospitalization a
265 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a
267 VID(ICU) patients), and patients with severe community-acquired pneumonia requiring ICU support (CAP(
268 iae is the most common causative organism in community-acquired pneumonia responsible for millions of
269 DSA/ATS 2007) criteria for predicting severe community-acquired pneumonia (SCAP) and evaluate a healt
270 f viral infections in the etiology of severe community-acquired pneumonia (SCAP) was prospectively ev
272 overgrowth, enteric infection, and possibly community-acquired pneumonia, spontaneous bacterial peri
275 common virus was primarily associated with a community-acquired pneumonia syndrome and caused substan
276 a pathogenic bacterium and a major cause of community-acquired pneumonia that could be fatal if left
277 iratory failure as a consequence of a severe community-acquired pneumonia that required central venou
278 cardiac complications occur in patients with community-acquired pneumonia, their incidence, timing, r
279 Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-conf
280 ts) and patients admitted with sepsis due to community-acquired pneumonia to 29 ICUs in the UK (secon
281 ed in AMs from patients at increased risk of community-acquired pneumonia, to address the requirement
282 pneumoniae is a major causative pathogen in community-acquired pneumonia; together with influenza vi
286 4.7%, 78.2%, 75%, and 87%, respectively, for community-acquired pneumonia validated against a blinded
287 ary outcomes were hospitalization because of community-acquired pneumonia (validated by chart review)
288 s with an episode of outpatient or inpatient community-acquired pneumonia (validated by review of med
289 burden of hospitalization for children with community-acquired pneumonia was highest among the very
290 of 1343 inpatients and 944 outpatients with community-acquired pneumonia were followed up prospectiv
291 Research Team (PORT) risk class III-IV acute community-acquired pneumonia were randomly assigned (1:1
292 not be optimal as a first-line treatment for community-acquired pneumonia when it follows influenza.
293 tes mellitus is an important risk factor for community-acquired pneumonia, whereas the prevalence of
294 ce interval, 0.96 to 1.13) or of any case of community-acquired pneumonia, whether or not it required
295 o penicillin and macrolides in many cases of community acquired pneumonia, which has resulted in shif
296 of 278 consecutive patients hospitalized for community-acquired pneumonia, who were followed up until
297 tolerated in hospitalized older adults with community-acquired pneumonia with sepsis (CAP + S) not a
298 occus pneumoniae is the most common cause of community-acquired pneumonia worldwide, and interleukin-
299 ptococcus pneumoniae is the leading cause of community-acquired pneumonia worldwide, resulting in hig